Effect of Metrofim and Vildagliptin in Type II diabetes

Diabetes mellitus is a group of metabolic disorder characterized by hyperglycaemia and altered metabolism of lipid, protein and carbohydrate. In diabetes there is total or subtotal deficiency of insulin along incetine defice.Insulin and many oral hypoglycemic drugs and are available for the treatment of Type II still target HbA1c is not achived. Vildaglipton selective inhibitor of Dipeptidyl Peptidase-4 (DPP-4), the enzyme responsible for the rapid degradation of circulating Glucagon - like Peptide-1.It improves islet function in patients with type-2 diabetes by increasing both and cell responsiveness to glucose and decrease fasting plasma glucose (FPG) and postprandial glucose.Metformin is the most commonly prescribed first-line hypoglycaemic drug worldwide, but due to the progressive worsening of blood glucose control during the natural history of type-2 diabetes, combination therapy usually becomes necessary.Therefore, it was of interest to ascertain the efficacy and tolerability of Vildagliptin, Metformin alone and in combination of both in type-2 diabetic patients.We got encouraging result with combination.